Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 EPS of $0.21, $0.03 better than the analyst estimate of $0.18. Revenue for the quarter came in at $814.32 million versus the consensus estimate of $806.02 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2026 EPS of $0.93-$1.03, versus the consensus of $0.94. Amneal Pharmaceuticals sees FY2026 revenue of $3.05-3.15 billion, versus the consensus of $3.21 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.